ArticleBMC nephrology2025
Factors affecting response to furosemide stress test among critically ill hypoalbuminemic patients with AKI without prior albumin infusion.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury (AKI) is a common and serious condition often associated with hypoalbuminemia, which can influence the pharmacokinetics and efficacy of diuretics like furosemide. In critically ill patients, sepsis is the major cause of AKI, accounting for nearly 50% of cases.
objectiveTo evaluate whether AKI patients with hypoalbuminemia can respond to FST without albumin supplementation.
methodsThis is a prospective quasi-experimental study. Patients were obtained from the intensive care unit of Cairo University Hospital with AKI stages 1 and 2 with hypoalbuminemia. A bolus of furosemide was administered at a dose calculated to be 1-1.5 mg/kg in a single dose to patients without a prior diagnosis of kidney disease and clinical signs of hypovolemia.
resultsA total of 41 critically ill patients with AKI were enrolled, aged between 18 and 80 years, of whom 56.10% had diabetes mellitus, 53.70% were on at least one nephrotoxic medication, and 56.10% had sepsis as the cause of AKI. The median (IQR) albumin level was 1.9 g/dL (1.4-2.7). Among 41 hypoalbuminemic AKI patients included, 80.50% responded to FST without prior albumin infusion. Non-responders had significantly lower baseline serum albumin levels, median (IQR) 1(1-2) vs. 2 (1-3) g/dL, p < 0.002).
conclusionAKI patients with mild-to-moderate hypoalbuminemia may still respond to FST without albumin infusion, although response rates decline with the increasing severity of hypoalbuminemia. The FST remains a valuable predictive tool in hypoalbuminemic AKI patients but warrants further investigation to optimize its utility in this population. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.